Abstract
Endocrine therapy is an important treatment of estrogen receptor (ER) positive breast cancer. However, late relapse after completion of 5-year adjuvant endocrine therapy is still common. Extended endocrine therapy (EET) is a promising strategy to further reduce the risk of recurrence and increase the cure rate in early-stage patients. The decision-making to EET should be individually implemented by weighing the risk of late recurrence, menopausal status, side effects, and patients′ preference. Future studies are still needed to identify the patients who are most likely to benefit from EET. Key words: Breast neoplasms; Prognosis; Tamoxifen; Endocrine therapy
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
